1. Michael L. Avery
2727 Nelson Rd.
Longmont, Colorado 80503
(303) 502-6506
Mikeavery100@aol.com
EDUCATION
University of Kansas; Lawrence, KS
BS, Cell Biology, 1988
BGS, Microbiology, 1988
MA Microbiology, 1995
EXPERIENCE
Amgen Inc. Analytical Sciences and Process Development 2006- 2013
Associate Scientist
Analysis of in process and product samples by HPLC and CE. Developed technical
CE and CE-LIF analytical methods. Product characterization with peptide mapping
(LC/MS/MS), glycan identification (CE-LIF, HPLC, UPLC), SEC, CEX, AEX, and
HILIC. Biophysical analytical resource: Circular Dichroism and FTIR.
Support technical reports, method development reports and regulatory filings.
Advanced support of electronic data filing. (PD LIMS/ELN).
Sigma-Aldrich Biosciences 2004-2006
Analytical Chemistry Research Associate.
Responsibilities include quantification of immunoglobulins by capillary
electrophoresis (Beckman-Coulter PA800). Analysis of cell culture media for
amino acids and proteins by HPLC and GC.
3M Pharmaceuticals, Department of Pharmacokinetics and Drug Metabolism
Advanced Biochemical Pharmacologist 2002-2003
Responsibilities included support for, in vitro, drug metabolism assays, definitive
cross-species metabolic stability, metabolite identification, and P450 inhibition screening.
Developed protein binding studies for preclinical IND reports. Six Sigma team member
for metabolite profile and identification. Bioanalytical studies with LC/MS, ChromQuest,
MassLynx 3.5, PRISM, Documentum and Watson LIMS.
Quintiles. Kansas City, Missouri.
Biopharmaceutical Sciences/ADME 1999- 2001
Position required development and maintenance of bovine brain microvessel endothelial
cell culture (BBMEC) for CNS permeability screening. In vitro, plasma protein binding by
equilibrium dialysis and ultrafiltration. Responsibilities included working on GLP
Protocols, writing protocols and implementation, and writing reports for clients.
2. University of Kansas, Department of Pharmaceutical Chemistry.
Research Associate 1995-1999.
Research involving P450 induction and metabolism of placenta cell culture.
Responsibilities included HPLC method development for metabolism and permeability
studies in BeWo, Caco-2, and MDCK cells.
VA Medical Center, Department of Neurobiology, Kansas City, Missouri.
Research Associate 1992-1995
Laboratory research involved cell and tissue culture of neurodegenerative diseases.
Required development and purification of monoclonal antibodies, maintenance of cell
lines, isolation of astrocytes for in situ hybridization. Analytical research with FPLC and
HPLC.
University of Kansas, Department of Microbiology.
Graduate Teaching Assistant, 1990-1991.
University of Kansas, Department of Microbiology
Graduate Research, 1989-1991.
Thesis research project on the development and characterization of monoclonal
antibodies and anti-idotype polyclonal antibodies to STa enterotoxin produced by
Enterotoxigenic E. coli.
University of Kansas, Department of Microbiology.
Research Technician, 1988.
Research included cell and tissue culture, development of monoclonal antibodies,
maintenance of cell lines, characterization of monoclonal antibodies. Bioanalytical
studies with protein cross-linking, radiolabeling and protein purification (FPLC).
TECHNICAL EXPERIENCE
Cell and Tissue Culture. Experience with isolation of bovine brain microvessel
Endothelium for transport and receptor binding studies. Studies with cell lines
include: BeWo, Caco-2, Calu-3, HRP-1, and MDCK. Development and screening
hybridoma cells for monoclonal antibody characterization.
Bioanalytical Experience with PCR, southern and northern blotting, electrophoresis
(1D and 2D). ELISA and ligand binding studies. Protein purification (HPLC, ion exchange,
hydrophobic, size exclusion). Protein radio labeling studies with C14, H3, and I125.
Analytical characterization of protein therapeutics by HPLC, CE, and LC/MS/MS.
Pharmacokinetics/ADME. CYP induction, inhibition and metabolic stability studies.
In vitro, BBMEC assays for blood-brain barrier permeation. Protein binding studies by
Equilibrium dialysis and ultrafiltration.
3. ABSTRACTS
The Bovine Brain Microvessel Endothelial Cell (BBMEC) Model As an In Vitro Screen
For CNS Permeability. Thompson T.N., Avery M.L., Otis K.W., Hansen D.K., Broward
M.A., Broward-Partin S.M., Behlow H.W., Kelley M., and Scott D. ISSX 6th
International
Meeting. 2001. Munich, Germany.
A Quantitative Determination of P-Glycoprotein Efflux Transporter In Bovine Brain
Microvessel Endotheial Cells (BBMEC). Avery M.L., Otis K.W., Correll M.A.,
Broward-Partin S.M., Rose J.Q., and Thompson T.N. Quintiles, Inc Kansas City. MO
Presented at AAPS 2000. Indianapolis, Indiana.
Comparison of Drug Permeability between Monolayers of Brain Microvessel Endothelial
Cells (BBMEC) and Intestinal Epithelial Cells (Caco-2). Otis K.W., Correll M.A.,
Avery M.L., Hansen D.K., Yerino P.P., Behlow H.W., Broward-Partin S.M., Rose J.Q.,
Thompson T.N. Quintiles, Inc. Kansas City, MO. Presented at AAPS 2000. Indianapolis,
Indiana.
A High Throughput Methodology for the Investigation of Blood-Brain Barrier
Permeability, In Vitro. Hansen D.K., Yerino P.P., Behlow H.W., Otis K.W., Avery M.L.,
Wimmer P., Gerstenecker G., Miller T., and Toren P.C. Quintiles Inc., Kansas City, MO.
Presented at North American Bioanalytical Forum. 2000.
An Improved, Higher Throughput Model to Screen Multiple Analogs For CNS Penetration
Otis K.W., Hansen D.K., Behlow H.W., Broward S.M., Avery M.L., Thompson T.N., and
Scott D. Quintiles, Inc. Kansas City, MO. Presented at 27th
National Medicinal Chemistry
Symposium June 13, 2000.
The BBMEC Model for Facile Screening of CNS Permeation. Rose J.Q., Otis K.W.,
Hansen D.K., Behlow H.W., Broward S.M., Avery M.L., Thompson T.N., Burmaster S.D.,
Larsen D., Stuhler J., and Scott D., Quintiles, Inc. Kansas City, MO. Presented at Western
Regional AAPS May 2000.
Investigation of Functional Expression of P-Glycoprotein (P-gp) and Multidrug Resistant
Protein (MRP) in BeWo (Trophoblast) Monolayers, a Model of the Placenta Barrier.
Utoguchi N., Chandorkar G.A., Avery M.L., and Audus K.L., Department of Pharmaceutical
Chemistry, University of Kansas. Presented at AAPS 1998.
Insulin-like Growth Factor Binding Proteins (IGFBP’s) in Mouse Spinal Cord During
Development. Ma J.Y., Avery M.L., Arnold P.M., Citron B.A., and Festoff B.W.
4. Neurobiology Research Laboratory, VA Medical Center, Kansas City,. Presented at The
Society for Neuroscience 1995.
Insulin-like Growth Factor (IGFBP’s) and Their Regulation by Recombinant Human IGF-I
(rhIGF-I) in Amyotrophic Lateral Sclerosis (ALS). Yang S.X., Avery M.L., Stong D., and
Festoff B.W. VA Medical Center, Kansas City, MO. Presented at Cephalon Inc., 1995.
PUBLICATIONS
Avery M.L., Meek C.E., and Audus K.L., The Presence of Inducible Cytochrome P450’s
(CYP1A1:1A2) in Human Placenta and the Trophoblast-Like Cell Line BeWo. Placenta.
24(1) 45-52. 2003.
Otis K.W., Avery M.L., Broward-Partin S.M., Hansen D.K., Behlow H.W., Scott D.O.,
Thompson T.N. Evaluation of the BBMEC Model for Screening the CNS Permeability
of Drugs. Journal of Pharmacological and Toxicological Methods. 45, 71-77.2001
Avery M.L., Audus K.L., and Aced A. Determination of Substrate Permeability; In vitro,
by RP-HPLC and Convective Interaction Media (CIM) Coupled Disk HPLC. American
Biotechnology Laboratory. 17, 1999.
Foster K.A., Avery M.L., Yazdanian M., and Audus K.L. Characterization of the Calu-3 Cell
Line as a Tool to Screen Pulmonary Drug Delivery. International Journal of Pharmaceutics.
208, 1-11.2000.
Ernawati S., Seetharama J., Avery M., Makagiansar I., Tambunan U., Audus K., and
Siahaan T. Increasing Paracellular Porosity by E-Cadherin Peptides: Discovery of Bulge
and Groove Regions in the EC1-domain of E-cadherin. Pharmaceutical Research 19,
1170-1179. 2002
Makagiansar T., Avery M.L., Audus K.L., and Siahann T.J. Improving the Selectivity of
HAV-peptides in Modulating E-Cadherin E-Cadherin Interactions in the Intercellular
Junctions of MDCK Cell Monolayers. Pharmaceutical Research. 18, 446-453. 2001
Utoguchi N., Chandorkar G.A., Avery M.L., and Audus K.L. Functional Expression of
P-Glycoprotein in Primary Cultures of Human Cytotrophoblasts and BeWo Cells.
Reproductive Toxicology. 14, 217-224. 2000.
Avery M.L., and Audus K.L., Characterization of Cytochrome P450 in Human Placenta
and Xenobiotic Metabolism in BeWo Cell Culture. FASB Abstracts Part II A962. 1998.
Foster K.A., Oster C.G., Mayer M.M., Avery M.L., and Audus K.L., Characterization
of the A549 Cell Line as a Type II Pulmonary Epithelial Model for Drug Metabolism.
Experimental Cell Research. 243. 359-366.1998.
Shi F., Soares, M.J., Avery M.L., Zhang X., and Audus K.L., Permeability and Metabolic
Properties of a Trophoblast Cell Line (HRP-1) Derived from Normal Rat Placenta.
